293 related articles for article (PubMed ID: 28933411)
1. Mitochondrial Dysfunction in Lysosomal Storage Disorders.
de la Mata M; Cotán D; Villanueva-Paz M; de Lavera I; Álvarez-Córdoba M; Luzón-Hidalgo R; Suárez-Rivero JM; Tiscornia G; Oropesa-Ávila M
Diseases; 2016 Oct; 4(4):. PubMed ID: 28933411
[TBL] [Abstract][Full Text] [Related]
2. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
3. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
4. Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.
Arévalo NB; Lamaizon CM; Cavieres VA; Burgos PV; Álvarez AR; Yañez MJ; Zanlungo S
Front Mol Neurosci; 2022; 15():934820. PubMed ID: 35992201
[TBL] [Abstract][Full Text] [Related]
5. Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1.
Srikanth MP; Jones JW; Kane M; Awad O; Park TS; Zambidis ET; Feldman RA
Stem Cells Transl Med; 2021 Jul; 10(7):1081-1094. PubMed ID: 33656802
[TBL] [Abstract][Full Text] [Related]
6. Coenzyme Q
de la Mata M; Cotán D; Oropesa-Ávila M; Villanueva-Paz M; de Lavera I; Álvarez-Córdoba M; Luzón-Hidalgo R; Suárez-Rivero JM; Tiscornia G; Sánchez-Alcázar JA
Orphanet J Rare Dis; 2017 Feb; 12(1):23. PubMed ID: 28166796
[TBL] [Abstract][Full Text] [Related]
7. Autophagy and Lysosome Storage Disorders.
Ren H; Wang G
Adv Exp Med Biol; 2020; 1207():87-102. PubMed ID: 32671740
[TBL] [Abstract][Full Text] [Related]
8. Animal Models for the Study of Gaucher Disease.
Cabasso O; Kuppuramalingam A; Lelieveld L; Van der Lienden M; Boot R; Aerts JM; Horowitz M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003227
[TBL] [Abstract][Full Text] [Related]
9. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
10. Patients with Gaucher disease display systemic oxidative stress dependent on therapy status.
Kartha RV; Terluk MR; Brown R; Travis A; Mishra UR; Rudser K; Lau H; Jarnes JR; Cloyd JC; Weinreb NJ
Mol Genet Metab Rep; 2020 Dec; 25():100667. PubMed ID: 33335836
[TBL] [Abstract][Full Text] [Related]
11. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
12. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.
Kinghorn KJ; Grönke S; Castillo-Quan JI; Woodling NS; Li L; Sirka E; Gegg M; Mills K; Hardy J; Bjedov I; Partridge L
J Neurosci; 2016 Nov; 36(46):11654-11670. PubMed ID: 27852774
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
14. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders.
Plotegher N; Duchen MR
Trends Mol Med; 2017 Feb; 23(2):116-134. PubMed ID: 28111024
[TBL] [Abstract][Full Text] [Related]
16. Secondary Mitochondrial Dysfunction as a Cause of Neurodegenerative Dysfunction in Lysosomal Storage Diseases and an Overview of Potential Therapies.
Stepien KM; Cufflin N; Donald A; Jones S; Church H; Hargreaves IP
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142486
[TBL] [Abstract][Full Text] [Related]
17. Impaired parkin-mediated mitochondrial targeting to autophagosomes differentially contributes to tissue pathology in lysosomal storage diseases.
de Pablo-Latorre R; Saide A; Polishhuck EV; Nusco E; Fraldi A; Ballabio A
Hum Mol Genet; 2012 Apr; 21(8):1770-81. PubMed ID: 22215441
[TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
19. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells.
Awad O; Sarkar C; Panicker LM; Miller D; Zeng X; Sgambato JA; Lipinski MM; Feldman RA
Hum Mol Genet; 2015 Oct; 24(20):5775-88. PubMed ID: 26220978
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: A Review.
Stepien KM; Roncaroli F; Turton N; Hendriksz CJ; Roberts M; Heaton RA; Hargreaves I
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32796538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
